Pharmaceutical Executive-12-01-2018

Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.

The Commission’s gestures toward enacting formal standards to digitize health records are masking wider policy gaps.

Almost a year and a half later, key understandings have emerged to help companies better combat future data-breach attempts.

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by pharma to embed meaningful and holistic benefits from this capability is still a work in progress.

Sonalee Agarwal, head of value and evidence strategy for Alnylam, talks with Pharm Exec about the role of real-world evidence in the rare and ultra-rare disease space.

There is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.

Objective considerations when gauging investment.

Click the title above to open the Pharmaceutical December 2018 issue in an interactive PDF format.

With a reputation as a reliable, if somewhat unspectacular, marketplace, Malaysia has long appealed to life science investors lured in by the prospect of generating consistent returns.